Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2017-06-20

Clinical Trial Update: The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjuvant transarterial chemoinfusion for hepatocellular carcinoma with microvascular invasion after hepatectomy. The current status of …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: UNKNOWN